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background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, mostly autosomal dominant disease causing sudden cardiac 
death early in life. Mutations involving Ryanodine receptor and Calsequestrin (CASQ) genes have been implicated.
case: A 49-year-old African American female underwent an exercise stress test for exertional chest pain. At rest, her blood pressure was 140/90 
mmHg and ECG showed sinus bradycardia. Approximately 3 minutes into exercise, she developed chest pain along with a blood pressure of 250/86 
mmHg. ECG showed polymorphic ventricular rhythm at a rate of 210 bpm. Prompt administration of intravenous beta-blocker successfully terminated 
the arrhythmia.
Decision making: Coronary angiography, echocardiogram and cardiac MRI were normal excluding ischemia and structural cardiac disease. 
Her genetic testing revealed a rare heterozygous autosomal recessive CASQ2 mutation on short arm of chromosome 1 involving exon 2, resulting 
in a nucleotide and amino acid change of 261dupA and Ala88Fs respectively. On maximally tolerated dose of beta-blocker, the patient was 
asymptomatic. Follow-up treadmill stress test and holter monitor showed no recurrence of CPVT.
conclusion: We present this unusual case of CPVT in a relatively older, symptomatic African American female with a novel mutation in CASQ gene 
to increase the awareness of this fatal arrhythmia, to highlight the importance of beta-blockade and to add this rare mutation to the available 
limited genetic pool.
 
